摘要乙肝病毒引起的病毒性肝炎是世界范围内对人类健康的一个主要威胁。目前抗病毒治疗乙肝仍是最重要的一环。同时,超重和肥胖已成为全球公共卫生问题之一。国内有研究显示抗病毒药物（拉米夫定）效果和体重指数（body mass index,BMI）之间存有联系。而关于其他药物（如恩替卡韦）治疗乙肝效果和体重指数之间的联系报道较少。
3Alessandro Federico,Elena D’Aiuto,Francesco Borriello,Giusi Barra,Antonietta Gerarda Gravina,Marco Romano,Raffaele De Palma.Fat:A matter of disturbance for the immune system[J].World Journal of Gastroenterology,2010,16(38):476-4772. 被引量：12
8Fujimoto M,Tanahira C,Nishi M,et al. In non-obese patients, duration of action of rocuronium is directly correlated with body mass index[J]. Can J Anaesth,2013,60(6) :552-556. 被引量：1
9Cooper R, Mirakhur RK, Clarke RS, et al. Comparison of intubating conditions after administration of Org 9246 (rocuronium) and suxamethonium[ J]. Br J Ananesth, 1992,69(3) : 269-273. 被引量：1
10Kirov K, Motamed C, Decailliot F,et al. Comparison of the neuromuscular blocking effect of cisatracurium and atracurium on the larynx and the adductor pollicis [J ]. Acta Anaesthesiol Scand, 2004,48(5) :577-581. 被引量：1
